We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Analysis of Circulating DNA Predicts Prostate Cancer's Development of Drug Resistance

By LabMedica International staff writers
Posted on 15 Nov 2015
Print article
Image: Molecular model of the prostate cancer drug abiraterone (Photo courtesy of Wikimedia Commons).
Image: Molecular model of the prostate cancer drug abiraterone (Photo courtesy of Wikimedia Commons).
Analysis of prostate cancer DNA circulating in the bloodstream identifies a mutation that indicates whether the tumor will become resistant to the drug-of-choice abiraterone, and enables the physician to choose an alternative treatment.

Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance; therefore, determination of AR gene status using a minimally invasive assay would have broad clinical utility.

Towards this end, investigators at the Institute of Cancer Research (London, United Kingdom) developed a targeted next-generation sequencing approach amenable to plasma DNA, which covered all AR coding bases and genomic regions that have been linked to prostate cancer.

The investigators sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. They controlled for normal DNA in patients’ circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients).

Results revealed that patients with a specific mutation or an increase in the number of copies of the AR gene were 7.8 times less likely to have a reduction of more than 90% in their PSA (prostate specific antigen) levels, a widely used test to monitor the response of prostate cancer to treatment. The study also found that in about 15% of men given abiraterone who did not have either genetic aberration before starting treatment, it was acquired as resistance appeared and the drug stopped working. The mutation was detectable in the bloodstream several months before patients developed any physical symptoms.

Senior author Dr. Gerhardt Attard, clinician scientist at the Institute of Cancer Research, said, "The discovery of abiraterone was an important step forward for patients with advanced prostate cancer, but we know it does not work for all men, and we have been searching for a marker that will tell us in advance which men will benefit. We are delighted to have developed a test that appears to predict very accurately whether a patient will respond to abiraterone, and that it can be performed on blood samples—removing the need to take a biopsy. We are now planning a clinical trial involving up to 600 men in which we aim to prospectively show that men who are positive with our test have significantly greater benefit from chemotherapy in preference to abiraterone or similar drugs. Additionally, looking at tumor DNA in the blood of patients could potentially give us an overall picture of why the cancer is progressing all over the body, unlike a biopsy that only tells us about the area sampled."

The study was published in the November 4, 2015, online edition of the journal Science Translational Medicine.

Related Links:

The Institute of Cancer Research


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.